AlphaGen
Access AlphaGen
Company Narratives

Habib Rice Products FY26: Q4 Recovery Narrows the Loss, but Borrowing and Cash Burn Rise

Habib Rice Products narrowed its FY26 loss as Q4 sales and margins recovered, but negative operating cash flow and sharply higher borrowing leave funding discipline central.

Sep 22, 2026

Verdict

Habib Rice Products Limited ended FY26 with a materially smaller loss and a much better final quarter than a year earlier, but the recovery is not yet self-funding. Full-year sales rose 7.1% to Rs2.29 billion, gross margin improved to 8.8% from 8.0%, and the net loss narrowed 43.8% to Rs87.58 million. The strongest signal is the June quarter: derived from the audited full-year result less the officially reported nine-month numbers, Q4 sales rose about 19.8% year on year and gross margin recovered to roughly 7.0% from 2.5%, cutting the quarterly loss almost in half.

The weak point sits on the balance sheet and cash-flow statement. Inventory rose 16.5%, current liabilities grew 25.2%, funded borrowings excluding leases increased from Rs38.0 million to about Rs285.3 million, and net operating cash outflow widened to Rs129.88 million. A post-year-end decision to obtain up to US$500,000 of unsecured, interest-free sponsor funding for working capital reinforces the point: earnings are improving, but working-capital and funding discipline now matter as much as the income statement.

Company and reporting basis

Company Name: Habib Rice Products Limited

Ticker: HRPL

Reporting period: Year ended June 30, 2026, with Q4 FY26 derived from the audited annual result and the previously announced unaudited nine-month result.

Reporting basis: Audited company-only financial statements in Pakistani rupees. The Board approved the annual audited financial statements on September 22, 2026. The company produces rice-based starch sugars and proteins; this product mix makes broad sugar-mill comparisons a poor economic proxy even though PSX classifies HRPL under Sugar & Allied Industries.

AlphaGen model outputs

Alpha QoQ Score: 35.57

TTM Performance Score: 41.13

3Y Business Perf Score: 34.49

Sector Leadership Score: 58.22

These four scores are AlphaGen model outputs, not figures reported by Habib Rice Products Limited.

Results at a glance

  • FY26 net sales rose 7.1% to Rs2.288 billion from Rs2.136 billion, while gross profit increased 18.1% to Rs200.69 million. Gross margin improved to 8.77% from 7.96%.
  • The full-year loss before levies and minimum/final tax narrowed to Rs59.39 million from Rs123.16 million. Net loss improved 43.8% to Rs87.58 million from Rs155.71 million; EPS improved to negative Rs2.19 from negative Rs3.89.
  • Distribution costs fell 38.1% to Rs99.07 million, while administrative expenses were broadly flat at Rs143.14 million. Other income dropped sharply to Rs1.19 million from Rs17.17 million, so the turnaround did not depend on a repeat of last year's non-operating income.
  • Finance costs more than doubled to Rs16.63 million from Rs7.56 million, consistent with a much larger borrowing footprint.
  • Derived Q4 sales were about Rs536.22 million versus Rs447.50 million a year earlier. Q4 gross profit rose to Rs37.29 million from Rs11.03 million, gross margin improved to about 6.96% from 2.46%, and the quarterly net loss narrowed to about Rs37.49 million from Rs73.40 million.
  • Net cash used in operating activities worsened to Rs129.88 million from Rs13.48 million. Capital expenditure was Rs101.64 million, while financing activities supplied Rs159.45 million, largely through new short- and long-term borrowings.

What improved

The most important improvement is that FY26's smaller loss came from better operating economics rather than a large one-off gain. Gross profit rose faster than revenue, and distribution costs fell by roughly Rs60.9 million. After gross profit, distribution, administration, other expenses and other income, the pre-finance operating loss was about Rs42.8 million, versus roughly Rs115.6 million in FY25. That is a meaningful narrowing of the recurring operating deficit.

Management's half-year review provides part of the explanation for the earlier improvement. It cited higher local and export sales, greater rice grinding and production, better capacity utilization, lower repair and maintenance costs, more economical laboratory testing, selective trade-show spending and lower local and foreign commissions. The full-year fall in distribution costs is directionally consistent with those measures, although the September annual result notice does not provide a fresh full-year causal bridge, so those half-year explanations should not be mechanically extended to every quarter.

The final quarter also matters because FY26 was not a straight-line recovery. Q3 had been weak: the March quarter produced only Rs21.30 million of gross profit on Rs517.93 million of turnover. By contrast, the derived June quarter produced Rs37.29 million of gross profit on Rs536.22 million of sales. Year on year, Q4 revenue grew 19.8%, gross profit more than tripled from an unusually weak base, and distribution cost fell 45.6%. That combination reduced the Q4 net loss by roughly 49%.

The annual gross margin of 8.77% still remains modest, but it is better than FY25's 7.96%. This matters because management's half-year review identified steep energy-cost escalation as pressure on production margins and increased Sorbitol imports under the prevailing tax and tariff regime as a competitiveness challenge for local manufacturing. A margin recovery that can be sustained through production and cost discipline would therefore be higher quality than a recovery driven only by ancillary income.

What weakened / needs attention

Cash conversion deteriorated sharply. Cash used in operations before taxes and finance payments was Rs83.00 million, compared with Rs28.13 million generated in FY25. After taxes, finance costs and long-term deposits, net operating cash outflow reached Rs129.88 million. This is the clearest reason the earnings improvement should not yet be treated as a completed turnaround.

Inventory is a major part of that story. Stock in trade rose to Rs532.39 million from Rs456.95 million, a 16.5% increase, and represented about 62% of current assets. Stores and spares were another Rs125.32 million. Trade receivables, by contrast, fell 55% to Rs11.79 million, so the working-capital build was not driven by customer receivables. The published annual result does not provide the detailed cash-flow working-capital reconciliation, so it would be inappropriate to assign the entire operating cash deficit to inventory alone; however, the balance-sheet movement makes inventory conversion a key next-period test.

Liquidity also became more dependent on borrowing. Long-term financing increased to Rs113.8 million from Rs38.0 million, while secured short-term borrowing reached Rs171.52 million from nil. Excluding lease liabilities, funded borrowings therefore rose to roughly Rs285.3 million. Current liabilities increased to Rs684.17 million from Rs546.63 million, while current assets rose more slowly to Rs858.47 million, reducing the current ratio to about 1.25 times from 1.44 times.

The higher funding footprint is already visible in the income statement. Finance costs increased 119.9% to Rs16.63 million. In the derived June quarter alone, finance cost was about Rs5.95 million versus less than Rs1 million a year earlier. With the State Bank of Pakistan policy rate at 11.5% as of September 2026, financing remains a material variable for the next cycle even if HRPL's actual borrowing rates and repricing schedules are not disclosed in the result notice.

Revenue and margin pattern: recovery, but still volatile

FY26 revenue growth of 7.1% looks modest at first glance, but the intra-year pattern was volatile. The first half benefited from stronger local and export sales and better production according to management. The March quarter then saw turnover fall year on year and gross margin compress heavily. The derived June quarter reversed part of that damage, with stronger sales and a large margin improvement against a very weak Q4 FY25 comparison.

That sequencing is useful because it shows what has and has not been proven. HRPL has demonstrated that it can restore sales and gross profit when utilization, cost control and demand align. It has not yet demonstrated stable quarterly margins or consistent positive operating cash generation. For the next result, the more important question is whether Q4's better gross economics persist without another step-up in inventory or borrowings.

Input supply and competitive context

HRPL's economics are tied to rice availability because the company manufactures rice-based starch sugars and protein products. Pakistan's Economic Survey for FY26 reported rice production of 9.99 million tonnes, up 2.8% from 9.72 million tonnes a year earlier. That is directionally supportive for domestic raw-material availability, but it does not establish HRPL's purchase price, quality mix or procurement advantage; those factors are not disclosed in the annual result notice.

The more structural pressure is imported Sorbitol. In its half-year review, management said increased imports under the prevailing tax and tariff regime were hurting the competitiveness of locally manufactured products, alongside high energy costs. That pressure should be treated as recurring rather than exceptional. FBR's current customs tariff remains the relevant first-party regulatory source to track for changes in import treatment, while HRPL's own disclosures will be needed to establish whether any policy change materially alters realized pricing or volumes.

A conventional listed-peer comparison is not especially useful here. HRPL's product set spans rice-based sweeteners, polyols and protein concentrates, while the PSX Sugar & Allied group largely contains businesses with different raw materials, pricing structures and regulatory exposures. Sector data are therefore more useful as context than as a direct margin benchmark.

Balance sheet and capital allocation

Total assets increased 9.1% to Rs1.509 billion, supported by higher property, plant and equipment and working capital. Net property, plant and equipment increased 9.4% to Rs635.69 million. The cash-flow statement shows Rs101.64 million of capital expenditure during the year, indicating that HRPL continued to invest in the operating asset base despite remaining loss-making.

Equity fell 11.0% to Rs706.13 million, almost exactly reflecting the annual loss, while current liabilities expanded materially. The balance sheet therefore shows a company funding both operations and capital expenditure through a combination of existing equity, larger borrowings and working-capital liabilities. This structure is manageable only if the operating improvement begins to convert into cash.

There is also an important difference between balance-sheet cash and the cash-flow figure. Cash and bank balances were Rs10.96 million at June 30, but the cash-flow statement reported ending cash and cash equivalents of negative Rs60.56 million. The result announcement does not include the detailed note reconciling those two measures. Until the annual report provides that reconciliation, the conservative reading is that headline balance-sheet cash should not be viewed in isolation from short-term financing.

Post-period liquidity support

On July 14, 2026, after the year end, the Board approved an unsecured loan of up to US$500,000 from sponsor shareholder Gaffar A. Habib to meet working-capital requirements. The loan is interest-free and repayable on request by mutual consent, subject to cash-flow availability. Repayment is to be made in Pakistani rupees at the prevailing US dollar/rupee rate on the actual repayment date.

This is economically important in two ways. First, interest-free sponsor funding can reduce the incremental cash interest burden relative to conventional borrowing. Second, because the rupee repayment amount is linked to the exchange rate at repayment, the principal carries currency-linked variability. Most importantly, the company's stated purpose for the facility—working capital—corroborates the cash-flow pressure visible in the FY26 statements.

Recurring versus non-recurring earnings

  • More recurring / operational: product sales, gross margin, distribution and administrative costs, energy and production efficiency, finance costs on the borrowing base, and the competitive pressure from imported substitutes.
  • Less recurring / volatile: other income fell from Rs17.17 million to Rs1.19 million. FY26's improvement did not rely on a large positive other-income contribution, which improves the quality of the year-on-year loss reduction.
  • Tax and levies: levies, minimum tax and final tax were Rs28.18 million versus Rs26.21 million. With the company still loss-making before these charges, fixed/minimum-tax type burdens remain relevant to the path back to net profitability.
  • Historical pattern: PSX's published annual history shows profit in FY22-FY23, then losses in FY24-FY26. FY26 therefore represents improvement within a loss-making phase, not yet a return to profitability.

Dividend and corporate actions

The September 22 annual-result notice set the 46th Annual General Meeting for October 28, 2026 and the book-closure period for October 21-28. The result notice did not announce a new cash dividend or other shareholder distribution. Capital allocation is therefore currently centered on operations, capex and liquidity rather than a newly announced payout.

Key risks

  • Working-capital absorption: inventory remains high and operating cash flow is negative despite the smaller accounting loss.
  • Funding cost and leverage: borrowings rose sharply and finance cost more than doubled; further working-capital needs could keep financing pressure elevated.
  • Sorbitol import competition: management continues to identify imported product under the prevailing tax/tariff regime as a competitiveness challenge for local production.
  • Energy and utility costs: management's half-year review cited steep escalation in energy costs as a continuing pressure on production margins.
  • Quarterly margin volatility: the strong H1, weak Q3 and improved Q4 sequence shows that one quarter's margin should not be extrapolated without confirmation.

What to monitor next

  • Gross margin: whether Q4's roughly 7.0% margin is sustained or improves, rather than falling back toward the March-quarter trough.
  • Inventory conversion: whether stock in trade begins to fall relative to sales and whether operating cash flow moves materially toward breakeven.
  • Borrowings and finance cost: whether short-term borrowing stabilizes after the FY26 increase and whether sponsor funding substitutes for more expensive debt.
  • Sales mix: management's next disclosure on local versus export demand, production/grinding levels and product mix, especially for Sorbitol and higher-value rice-based ingredients.
  • Regulatory treatment of imports: any tax or tariff change affecting imported Sorbitol and the competitive gap with domestic production.
  • Capex returns: whether the Rs101.64 million FY26 capital expenditure contributes to better utilization, lower unit costs or stronger sales without further working-capital strain.

Bottom line

FY26 is a genuine improvement in HRPL's income statement: revenue grew, gross margin recovered, distribution costs fell sharply and the net loss nearly halved. The June quarter strengthens that interpretation because sales, gross profit and the quarterly loss all improved materially versus the prior-year final quarter.

But the cash-flow and balance-sheet evidence prevent a clean turnaround label. Operations consumed cash, inventory rose, debt increased sharply, finance cost doubled and the company subsequently sought sponsor funding for working capital. The next result will therefore be judged less by whether the loss narrows again and more by whether better margins finally translate into lower inventory intensity, positive cash conversion and a more stable funding requirement.

Sources

Explore more research

All articles